Pant, Shubham

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 1,222

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation

Bekaii-Saab, T. S., Yaeger, R., Spira, A. I., Pelster, M. S., Sabari, J. K., Hafez, N., Barve, M., Velastegui, K., Yan, X., Shetty, A., et al. (2023) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 313

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 308

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., et al. (2024) · Nature Medicine

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 267

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy

Pancreatic and Hepatic Oncology ResearchVirus-based gene therapy research

Cited by 166

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchColorectal Cancer Treatments and Studies

Cited by 147

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 93

Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer

Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 85

Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates

Kalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · Nature Communications

Extracellular vesicles in diseaseRNA Interference and Gene Delivery

Cited by 70

Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer

Henry, J. T., Coker, O., Chowdhury, S., Shen, J. P., Morris, V. K., Dasari, A., Raghav, K., Nusrat, M., Kee, B., Parseghian, C., et al. (2021) · JCO Precision Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 66

524P A Phase I, Open-Label, Dose-Escalation Trial of BI 1701963 in Patients (Pts) with KRAS Mutated Solid Tumours: A Snapshot Analysis

Johnson, M. L., Gort, E., Pant, S., Lolkema, M. P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U., Riemann, K., Kitzing, T., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 34

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

Pant, S., Furqan, M., Abdul-Karim, R. M., Chung, V., Devoe, C. E., Johnson, M. L., Leal, A. D., Park, H., Wainberg, Z. A., Welkowsky, E., et al. (2022) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 28

Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).

Ngoi, N., Scholefield, E. L., Parini, V., Huang, R. S. P., Janovitz, T., Danziger, N., Levy, M. A., Pant, S., Javle, M. M., Ross, J. S., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 7